Delta sleep-inducing peptide, usually called DSIP, has a name that sounds like a clinical promise. A name is not an outcome. Evidence needs to show what happened to sleep, how it was measured and whether the tested preparation resembles the product being discussed.

The human evidence needs context

A small double-blind study in 16 people with chronic insomnia reported changes in some objective sleep measures but not in several other measures, including subjective sleep quality. The authors concluded that short-term treatment was unlikely to provide major therapeutic benefit. This older study is useful because it shows why a favorable result on selected measurements should not be summarized as a proven sleep treatment. Double-blind DSIP insomnia study

A small trial also has limited ability to estimate uncommon harms, long-term effects or the range of responses across different causes of insomnia. It cannot support a universal prediction of deeper sleep or better daytime performance.

Route and formulation remain separate questions

Evidence for one preparation and route cannot establish the performance of a nasal spray. Nasal delivery requires its own information about formulation, exposure, local tolerability and clinical outcomes. A raw-material certificate would not answer those clinical questions.

FDA's bulk-substance safety information identifies important gaps for DSIP-related use. Those gaps should be visible alongside historical research rather than replaced with a reassuring description of a naturally occurring peptide. FDA safety concerns for certain bulk drug substances

AXON's educational conclusion is that DSIP remains a topic requiring careful evidence qualification. This review did not verify a nasal formulation with evidence sufficient for a sleep-treatment recommendation. Persistent sleep problems deserve assessment of their cause and appropriate clinical care. The article contains no spray schedule, preparation directions or claim that DSIP can replace established insomnia treatment.